|
| N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea Basic information |
Product Name: | N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea | Synonyms: | N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea;NK 252;NK252;Urea, N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-N'-(2-pyridinylmethyl)-;NK-252 >=98% (HPLC);NK-252,NK252,NK 252,inhibit,Inhibitor,Keap1-Nrf2;1-(5-(Furan-2-yl)-1,3,4-oxadiazol-2-yl)-3-(pyridin-2-ylmethyl)urea | CAS: | 1414963-82-8 | MF: | C13H11N5O3 | MW: | 285.26 | EINECS: | | Product Categories: | | Mol File: | 1414963-82-8.mol | ![N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea Structure](CAS/20200611/GIF/1414963-82-8.gif) |
| N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea Chemical Properties |
density | 1.408±0.06 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMSO: soluble20mg/mL, clear | pka | 11.50±0.70(Predicted) | form | powder | color | white to beige |
Hazard Codes | Xn | Risk Statements | 22 | WGK Germany | 3 |
| N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea Usage And Synthesis |
Description | NK 252 is a Nrf2 activator that interacts directly with the domain containing the Nrf2-binding site of Keap1. At 1.36 μM, it is reported to activate the NQO1-antioxidant response element in a luciferase reporter gene assay two-fold above background. NK 252 has been shown to downregulate the expression of fibrogenic genes, producing antifibrotic effects in a rat model of non-alcoholic steatohepatitis. | Uses | NK 252 is a Nrf2-activator. It exhibits a greater Nrf2-activating potential than OPZ. | storage | Store at +4°C | references | [1]. shimozono r, asaoka y, yoshizawa y, et al. nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. mol pharmacol. 2013 jul;84(1):62-70. [2]. kiue a, sano t, naito a, et al. reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse p388 leukemia in vivo and in vitro. jpn j cancer res. 1990 oct;81(10):1057-64. |
| N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea Preparation Products And Raw materials |
|